Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCHEDULE I/SCHEDULE II DRUGS 1993 PROPOSED PRODUCTION QUOTAS

Executive Summary

SCHEDULE I/SCHEDULE II DRUGS 1993 PROPOSED PRODUCTION QUOTAS from the Drug Enforcement Administration permit pharmaceutical manufacturers to produce 5,066,000 grams of hydrocodone, 1,175,000 more grams than the proposed 1992 quota for the narcotic analgesic/antitussive. The DEA list for 1993 contains proposed quotas for 14 Schedule I controlled drugs and 36 Schedule II controlled substances. DEA announced the proposed quotas in the Sept. 22 Federal Register. The 1993 production level for another Schedule II drug, morphine (for sale) is 6,378,000 grams, 1,441,000 grams more than the drug's proposed 1992 level. The proposed quotas provide for 2,948,000 grams of oxycodone (for sale), 191,000 more grams than the amount permitted in 1992 and allows for 50,900 grams of fentanyl, 2,400 grams more than last year. The quota for codeine (for sale) is 63,613,000 grams, 113,000 less than the 1992 proposed quota.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021536

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel